Royalty Pharma Plc Earnings

Royalty Pharma Plc’s revenue fell -0.34% since last year same period to $594Mn in the Q4 2024. On a quarterly growth basis, Royalty Pharma Plc has generated 5.19% jump in its revenue since last 3-months.

Royalty Pharma Plc’s net profit fell -57.92% since last year same period to $208Mn in the Q4 2024. On a quarterly growth basis, Royalty Pharma Plc has generated -61.76% fall in its net profits since last 3-months.

Royalty Pharma Plc’s net profit margin fell -57.78% since last year same period to 35.02% in the Q4 2024. On a quarterly growth basis, Royalty Pharma Plc has generated -63.65% fall in its net profit margins since last 3-months.

Royalty Pharma Plc’s price-to-earnings ratio after this Q4 2024 earnings stands at 17.45.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 1.05 - a 13.33% jump from last quarter’s estimates.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 1.05.

Royalty Pharma Plc’s earning per share (EPS) jumped 0.1% since last year same period to 1.15 in the Q4 2024. This indicates that the Royalty Pharma Plc has generated 0.1% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Royalty Pharma Plc’s return on assets (ROA) stands at 0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Royalty Pharma Plc’s return on equity (ROE) stands at 0.13.

Royalty Pharma Plc declared 0.21 dividend per share during the earnings announcement for Q4 2024.